J. Marsden et al., Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible?, FERT STERIL, 73(2), 2000, pp. 292-299
Objective: To evaluate the feasibility of conducting a large randomized tri
al of HRT in symptomatic women with early-stage breast cancer.
Design: Open randomized study.
Setting: Outpatient clinics at The Royal Marsden and St. George's Hospitals
, London.
Patient(s): One hundred postmenopausal women with early-stage breast cancer
, experiencing vasomotor symptoms and/or vaginal dryness.
Intervention(s): Randomization (1:1) to HRT or no WRT for 6 months.
Main Outcome Measure(s): Acceptance, continuance rates, and the reasons eli
gible women declined study entry.
Result(s): Acceptance (38.8%) and continuance rates (>80%) were encouraging
. The efficacy of HRT did not appear to be antagonized with concomitant tam
oxifen. Seventy-five percent of women continued HRT after the study ended.
Three women developed metastatic disease. Two used HRT.
Conclusion(s): Despite informed consent, a national UK randomized trial of
HRT should be feasible and has now been planned. Successful implementation
necessitates the provision of information about HRT and the estrogen defici
ency side effects of breast cancer therapy to health professionals and wome
n with breast cancer. (Fertil Steril(R) 2000;73:292-9. (C) 2000 by American
Society for Reproductive Medicine).